Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Ytelse og hørselsrelaterte resultater hos voksne implantert med det CI622D deksametason-eluerende cochleaimplantatet sammenlignet med de implantert med et standard cochleaimplantat (CI622) (DETECT)

5. oktober 2026 oppdatert av: Cochlear

En pivotal, prospektiv, multisenter, randomisert kontrollert, blindet undersøkelse som evaluerer effektiviteten av en deksametason-eluerende slank rett elektrode (CI622D) i reduksjon av impedans sammenlignet med en standard slank rett elektrode (CI622) i en nylig implantert voksenpopulasjon Postlingvistisk, bilateralt, moderat alvorlig til dyptgående sensorineuralt hørselstap.

This clinical study will test a newly developed cochlear implant known as CI622D. This experimental cochlear implant has been designed to slowly release a drug called dexamethasone. Dexamethasone works to ease inflammation, which is common after any surgical procedure. The goal is to learn if there are added benefits in implant performance and hearing outcomes with the dexamethasone-releasing cochlear implant (CI622D) vs. the standard cochlear implant (CI622) without dexamethasone. The study will be conducted in adults with sensorineural hearing loss, a type of hearing loss caused by damage to the inner ear or auditory nerve. The study participants will undergo a series of tests that include testing their implant and their hearing. They will also complete questionnaires to see how they rate their hearing ability and their overall general health.

Studieoversikt

Studietype

Intervensjonell

Registrering (Faktiske)

50

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • New South Wales
      • Sydney, New South Wales, Australia
        • Westmead Private Hospital
      • Sydney, New South Wales, Australia
        • Royal Prince Alfred Hospital
      • Sydney, New South Wales, Australia
        • Macquarie University
    • Victoria
      • Melbourne, Victoria, Australia
        • St Vincent Private Hospital
      • Melbourne E., Victoria, Australia
        • Royal Victorian Eye and Ear Hospital
      • Lille, Frankrike
        • Centre Hospitalier Universitaire de Lille
      • Paris, Frankrike
        • Hôpital Universitaire Pitié-Salpêtrière
      • Toulouse, Frankrike
        • Centre Hospitalier Universitaire Toulouse
      • Manchester, Storbritannia
        • Manchester Royal Infirmary
    • Freiburg Im Breisgau
      • Freiburg im Breisgau, Freiburg Im Breisgau, Tyskland
        • Universitätsklinikum Freiburg
    • Lower Saxony
      • Hanover, Lower Saxony, Tyskland
        • Medizinische Hochschule Hannover

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Aged 18 years or older (at time of consent)
  • Clinically established post-linguistic bilateral moderately severe to profound sensorineural hearing loss
  • Meets local candidacy criteria for cochlear implantation
  • Compromised functional hearing with a hearing aid in the ear to be implanted
  • Willing to participate in and comply with all requirements of the protocol, including willingness to be randomised to either arm
  • Evidence of pneumococcal vaccination (e.g., Pneumovax) according to local guidelines prior to randomisation
  • Candidate is proficient in the language used to assess speech perception performance
  • Willing and able to provide written informed consent.

Exclusion Criteria:

  • Planned for a partial insertion of the electrode array
  • Intra-axial (within the brain) lesions or deafness due to lesions of the acoustic nerve affecting the ear to be implanted
  • Middle ear infection (including acute otitis media, chronic otitis media, suppurative otitis media, or serous drainage) in the ear to be implanted either at the time of surgery or within 3 months prior to enrolment
  • Active autoimmune disease or active immunosuppressive therapy
  • Any of the following in the ear to be implanted within 3 months prior to enrolment: history of prior otologic surgery including grommets, or tympanic membrane perforation
  • Previously reported diagnosis of auditory neuropathy, in the ear to be implanted
  • Previously reported diagnosis, in the ear to be implanted, of Large Vestibular Aqueduct Syndrome (LVAS), Meniere's disease, or cochlear hydrops
  • Ossification, otosclerosis, malformation or any other cochlear anomaly, such as common cavity, that might prevent complete insertion of the electrode array, as confirmed by imaging, in the ear to be implanted
  • Current cerebrospinal fluid (CSF) shunts or drains, existing perilymph fistula, temporo- parietal skull fracture or CSF leaks
  • History of bacterial meningitis
  • Known allergic reaction or contraindication to dexamethasone or corticosteroids
  • Severe, or poorer, bilateral sensorineural hearing loss prior to 5 years of age, as reported by the subject
  • Severe, or poorer, sensorineural hearing loss of more than 20 years, as reported by the subject, in the ear to be implanted
  • Prior cochlear implantation, in either ear
  • Medical plan for cochlear implantation during the clinical investigation, contralateral to the ear to be implanted
  • Medical or psychological conditions that contraindicate general anaesthesia, surgery or participation in the clinical investigation, as determined by the investigator
  • Women who are pregnant
  • Unrealistic expectations on the part of the subject, regarding the possible benefits, risks, and limitations that are inherent to the surgical procedure(s) and prosthetic devices as determined by the Investigator
  • Additional disabilities that may affect the subject's participation or safety during the clinical investigation, as determined by the Investigator
  • Unable or unwilling to comply with the requirements of the clinical investigation as determined by the Investigator
  • Investigator site personnel directly affiliated with this study and/or their immediate families; immediate family is defined as spouse, parent, child, or sibling to the study candidate
  • Cochlear employees or employees of Contract Research Organisations or contractors engaged by Cochlear for the purposes of this investigation
  • Current participation, or participation in another interventional clinical study/trial in the past 30 days, involving an investigational drug or device (unless Cochlear sponsored and determined by investigator or Sponsor to not impact this investigation)
  • Subjects recruited at a French site who are not affiliated with social security
  • Subjects recruited at a French site who are under legal protection.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: CI622D

Investigational Medical Device (IMD)

A dexamethasone-eluting Slim Straight electrode

Aktiv komparator: CI622

An approved medical device

A standard Slim Straight electrode

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Difference in the mean impedance between CI622D and CI622
Tidsramme: 6 months post-activation

Mean monopolar impedance measured across the active electrodes of the implant for each participant.

6 months post-activation

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of Treatment-Emergent Adverse Events of the CI622D and CI622
Tidsramme: Throughout study (12 months)

Percentage of the number of participants who experience an adverse event for the CI622D group and the CI622 group

Throughout study (12 months)
Difference in the proportion of participants with preservation of low frequency residual hearing with CI622D compared with CI622
Tidsramme: Pre-implantation to 6 months post activation

The proportion of participants achieving ≤ 30 dB change in the low frequency pure tone average (LFPTA) (250 Hz and 500 Hz). This measure will be applied to the subgroup of participants who have a LFPTA < 80 dB HL at the pre-operative baseline.

Pre-implantation to 6 months post activation
Mean change (within-subject) in word recognition score in the preferred unilateral listening mode in quiet with the CI622D
Tidsramme: Pre-implantation to 6 months post-activation

Change in percent correct word recognition score

Pre-implantation to 6 months post-activation
Mean change (within-subject) in word recognition score in the preferred bilateral listening mode in quiet with the CI622D
Tidsramme: Pre-implantation to 6 months post-activation

Change in percent correct word recognition score

Pre-implantation to 6 months post-activation
Difference in mean (within-subject) change in word recognition score in the preferred unilateral listening mode in quiet with the CI622D compared with CI622
Tidsramme: Pre-implantation to 12 months post-activation

Change in percent correct word recognition score

Pre-implantation to 12 months post-activation
Difference in mean (within-subject) change in word recognition score in the preferred bilateral listening mode in quiet from pre-implantation to post-activation with CI622D compared with CI622
Tidsramme: Pre-implantation to 12 months post-activation

Change in percent correct word recognition score

Pre-implantation to 12 months post-activation
Difference in mean (within-subject) change in sentence recognition score in noise in the preferred unilateral listening mode from pre-implantation to post-implantation with CI622D compared with CI622
Tidsramme: Pre-implantation to 12 months post-activation

Change in percent correct sentence recognition score (Matrix test + 10 SNR)

Pre-implantation to 12 months post-activation
Difference in mean (within-subject) change in sentence recognition score in noise in the preferred bilateral listening mode from pre-implantation to post-implantation with CI622D compared with CI622
Tidsramme: Pre-implantation to 12 months post-activation

Change in percent correct sentence recognition score (Matrix test + 10 SNR)

Pre-implantation to 12 months post-activation
Characterization of four-point nested impedances and monopolar impedance of the CI622D and CI622
Tidsramme: Activation, 12 months post-activation

Group mean impedance measured across the active electrodes for four-point nested impedance and MP1+2 impedance for the CI622D and CI622

Activation, 12 months post-activation
Characterization of mean estimated sound processor battery life for CI622D and CI622
Tidsramme: 12 months post-activation

The estimated sound processor battery life (hours per day) as calculated by the programming software

12 months post-activation
Difference in mean within-subject changes in global score on the Speech, Spatial, and Qualities of Hearing Scale (SSQ12) between CI622D and CI622
Tidsramme: Pre-implantation to 12 months post-activation

Speech, Spatial, and Qualities of Hearing Scale global score (SSQ-12). Scores range from 0 to 10, where higher scores indicate greater ability (less hearing disability).

Pre-implantation to 12 months post-activation
Difference in mean within-subject changes in global Health Utilities Index III (HUI3) between CI622D and CI622
Tidsramme: Pre-implantation to 12 months post-activation

Health Utilities Index (HUI 2/3) global score. Scores range from -0.36 to 1.00, where a negative score represents a state "worse than dead" and a top score of 1.00 is "perfect health".

Pre-implantation to 12 months post-activation

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Samarbeidspartnere

Etterforskere

  • Hovedetterforsker: Antje Aschendorff, University Hospital Freiburg

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

17. juni 2024

Primær fullføring (Faktiske)

5. november 2025

Studiet fullført (Faktiske)

6. mai 2026

Datoer for studieregistrering

Først innsendt

16. mai 2024

Først innsendt som oppfylte QC-kriteriene

16. mai 2024

Først lagt ut (Faktiske)

22. mai 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

8. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

5. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere